Literature DB >> 33689096

PYCR1 promotes bladder cancer by affecting the Akt/Wnt/β-catenin signaling.

Shuangkuan Du1, Yongjie Sui2, Wei Ren1, Jiancheng Zhou1, Chun Du1.   

Abstract

Pyrroline-5-carboxylate reductase 1 (PYCR1) plays a significant role in the malignant progression of various cancers. However, the role of PYCR1 in bladder cancer has not been well studied. This study was performed to evaluate the potential relevance of PYCR1 in bladder cancer. Our data revealed that PYCR1 expression was increased in bladder cancer tissues, and increased expression of PYCR1 was predictive of decreased survival rates. In bladder cancer cell lines, knockdown of PYCR1 caused significantly retarded cell growth and invasion, while PYCR1 overexpression accelerated cellular proliferation and invasion. Moreover, PYCR1 knockdown decreased levels of phosphorylated Akt, and enhanced activation of Wnt/β-catenin signaling. Akt inhibition markedly abrogated of PYCR1 overexpression-mediated activation of Wnt/β-catenin signaling. In addition, overexpression of β-catenin partially reversed PYCR1 knockdown-mediated tumor suppression. Notably, PYCR1 knockdown significantly impeded tumor formation and growth in bladder cancer cells in vivo. In conclusion, these data demonstrate that PYCR1 is highly expressed in bladder cancer and knockdown of PYCR1 exerts a remarkable inhibitory effect on tumor formation via downregulation of Akt/Wnt/β-catenin signaling. Our study suggests a potential role for PYCR1 in promoting bladder cancer progression and indicates that PYCR1 may be utilized as an attractive and promising anticancer target for treatment of bladder cancer.

Entities:  

Keywords:  Akt; Bladder cancer; PYCR1; Wnt; β-Catenin

Mesh:

Substances:

Year:  2021        PMID: 33689096     DOI: 10.1007/s10863-021-09887-3

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  1 in total

1.  Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer.

Authors:  Feng Cai; Yingying Miao; Chenyang Liu; Ting Wu; Simei Shen; Xin Su; Yi Shi
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

  1 in total
  6 in total

Review 1.  Proline metabolism in cancer.

Authors:  Pengyu Geng; Wangshu Qin; Guowang Xu
Journal:  Amino Acids       Date:  2021-08-14       Impact factor: 3.520

Review 2.  Proline Metabolism in Malignant Gliomas: A Systematic Literature Review.

Authors:  Magdalena M Sawicka; Karol Sawicki; Tomasz Łysoń; Barbara Polityńska; Wojciech Miltyk
Journal:  Cancers (Basel)       Date:  2022-04-17       Impact factor: 6.575

3.  Low-dose radiation exaggerates HFD-induced metabolic dysfunction by gut microbiota through PA-PYCR1 axis.

Authors:  Zhao Ju; Peiyu Guo; Jing Xiang; Ridan Lei; Guofeng Ren; Meiling Zhou; Xiandan Yang; Pingkun Zhou; Ruixue Huang
Journal:  Commun Biol       Date:  2022-09-10

4.  Survival and clinicopathological significance of PYCR1 expression in cancer: A meta-analysis.

Authors:  Yue Li; Jiahuan Xu; Pengchen Bao; Zhijing Wei; Lei Pan; Jiawei Zhou; Wei Wang
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

5.  Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.

Authors:  Inge Oudaert; Hatice Satilmis; Philip Vlummens; Wouter De Brouwer; Anke Maes; Dirk Hose; Elke De Bruyne; Bart Ghesquière; Karin Vanderkerken; Kim De Veirman; Eline Menu
Journal:  J Exp Clin Cancer Res       Date:  2022-02-01

Review 6.  PYCR, a key enzyme in proline metabolism, functions in tumorigenesis.

Authors:  Yutong Li; Juntao Bie; Chen Song; Minghui Liu; Jianyuan Luo
Journal:  Amino Acids       Date:  2021-07-17       Impact factor: 3.520

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.